CytomX Therapeutics appoints Chris Ogden as CFO effective June 15, 2024

CytomX Therapeutics, Inc.

Chris Ogden promoted from SVP Finance & Accounting to CFO, effective June 15, 2024.
Ogden continues as Principal Accounting and Financial Officer, roles held since September 2022.
Granted option to purchase 75,000 shares and RSU award for 17,500 shares under 2015 Equity Incentive Plan.
No family relationships or arrangements with other parties in connection with his appointment.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Chris Ogden

Chief Financial Officer

CTMX · CytomX Therapeutics, Inc.

Effective: 2024-06-15
Filed: June 17, 2024, 7:59 PM ET

On June 12, 2024, CytomX Therapeutics, Inc. (the “Company”) appointed Chris Ogden to serve as the Company’s Chief Financial Officer effective June 15, 2024 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Chris Ogden was appointed as Chief Financial Officer at CytomX Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On June 12, 2024, CytomX Therapeutics, Inc. (the “Company”) appointed Chris Ogden to serve as the Company’s Chief Financial Officer effective June 15, 2024 (the “Effective Date”).

View on SEC.gov

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-162652

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.